Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Abbott Stands Up to Obamacare

The health-reform bill established a pathway to approve biosimilars -- generic versions of biologic drugs -- but Abbott Labs (NYSE: ABT  ) is trying to block biosimilars of its megablockbuster Humira.

Abbott's argument, which holds for all biologics approved before the law was established, basically boils down to the fact that the drugs are too hard to make and therefore require the FDA to reveal Abbott's trade secrets to help the generic-drug makers get their products close enough to the original to have confidence that they have the same activity.

This "it's too hard to make" strategy has been used before. Sanofi (NYSE: SNY  ) tried to block Momenta Pharmaceuticals (Nasdaq: MNTA  ) and others from getting approval of generic versions of Lovenox. Didn't work. ViroPharma (Nasdaq: VPHM  ) argued generic versions of its antibiotic Vancocin needed clinical trials to prove they work, which was successful for quite a while until the FDA caved in. Teva Pharmaceuticals (Nasdaq: TEVA  ) doesn't want the FDA to approve generic copies of its multiple sclerosis drug Copaxone, arguing that it's too complex to copy.

Biologics, which are approved under a Biologic Licensing Application, are a degree more complex than the most complex drugs approved under a New Drug Application, so there's certainly an argument to be made here. I'm just not sure Abbott will be able to win.

The Hatch-Waxman law, which set up the pathway for approval of generic versions of drugs approved through NDAs, lets generic-drug makers use the clinical trial data of the brand-name drug to establish the efficacy of their generics. For most small molecule drugs, manufacturing isn't an issue since there are simple analytical tests to ensure the drug has the same chemical structure.

I think Abbott is probably right that the generic-drug makers will need some trade secrets to approve biosimilars, but I don't see how manufacturing trade secrets are any different than efficacy and safety trade secrets that the FDA currently lets generic-drug makers use under the Hatch-Waxman. That efficacy and safety data will also be needed for approval of biosimilars, which is provided under the new law.

Of course, Abbott doesn't have to win to be effective. Anything to slow down the eventual approval of biosimilars will result in continued de facto exclusivity beyond patent expirations.

And all of these arguments could be moot points if the Supreme Court throws out the health-care-reform bill or the Republicans take control of the government and repeal the law. You can find out other ways to benefit from the outcome of the election in the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election." Claim your copy here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories and Momenta Pharmaceuticals. Motley Fool newsletter services have recommended buying shares of Teva Pharmaceutical Industries and Momenta Pharmaceuticals. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 16, 2012, at 7:12 PM, mtghack wrote:

    Looks like the author is looking forward for a GOP legislature and White House. He's clearly under some delusion that having a Republican in the WH is good for the economy long term. With the GOP taken over by the Tea Party, social and religious "conservatism" right wing nuts and having pushed out the economic pragmatists, we'll see how that works out.

  • Report this Comment On May 30, 2012, at 4:33 AM, thidmark wrote:

    ^^^ This is one of the dumbest comments I've seen on TMF ... and that's saying something.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1888858, ~/Articles/ArticleHandler.aspx, 10/20/2016 5:52:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:01 PM
ABT $40.74 Up +0.73 +1.82%
Abbott Laboratorie… CAPS Rating: *****
MNTA $12.26 Up +0.57 +4.88%
Momenta Pharmaceut… CAPS Rating: ****
SNY $38.07 Up +0.55 +1.47%
Sanofi CAPS Rating: *****
TEVA $44.21 Up +0.87 +2.01%
Teva Pharmaceutica… CAPS Rating: ****
VPHM.DL $0.00 Down +0.00 +0.00%
ViroPharma CAPS Rating: ***